1. Home
  2. DCI vs CYTK Comparison

DCI vs CYTK Comparison

Compare DCI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Donaldson Company Inc.

DCI

Donaldson Company Inc.

HOLD

Current Price

$86.74

Market Cap

10.6B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$65.81

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCI
CYTK
Founded
1915
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Pollution Control Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6B
10.7B
IPO Year
2005
2004

Fundamental Metrics

Financial Performance
Metric
DCI
CYTK
Price
$86.74
$65.81
Analyst Decision
Buy
Strong Buy
Analyst Count
5
19
Target Price
$99.00
$89.26
AVG Volume (30 Days)
582.6K
1.7M
Earning Date
06-02-2026
05-05-2026
Dividend Yield
1.38%
N/A
EPS Growth
N/A
N/A
EPS
2.75
N/A
Revenue
$2,844,900,000.00
$13,368,000.00
Revenue This Year
$4.58
$7.37
Revenue Next Year
$5.18
$310.19
P/E Ratio
$31.29
N/A
Revenue Growth
4.05
N/A
52 Week Low
$79.47
$47.22
52 Week High
$112.84
$88.31

Technical Indicators

Market Signals
Indicator
DCI
CYTK
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DCI
CYTK

About DCI Donaldson Company Inc.

Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.9 billion in revenue in its fiscal 2026.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: